PharmaPoint: HER2-Positive Breast Cancer – Global Drug Forecast and Market Analysis to 2025

2017-06-24
Price :
Published : Jun-2017
No. of Pages : 416

PharmaPoint: HER2-Positive Breast Cancer – Global Drug Forecast and Market Analysis to 2025

Summary

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies using numerous combinations of chemotherapy with Herceptin, Perjeta, and the tyrosine kinase inhibitor (TKI) Tykerb (lapatinib). During the forecast period from 2015-2025, GlobalData expects that the HER2-positive market will grow due to the launch of HER2-targeted agents in the early disease setting and the aging populations in the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and China.

Following the patent expiry of Herceptin and the subsequent highly anticipated introduction of trastuzumab biosimilars during the forecast period, the market is expected to face its biggest barrier to growth to date. Despite a lack of game-changing innovation in the HER2-positive market, the pipeline is diverse with several agents being investigated in the extended adjuvant and metastatic settings. A number of these agents are looking to address the greatest unmet need for HER2-positive breast cancer patients-brain metastases-which typically occur in the later lines of metastatic therapy and are caused by increasingly resistant disease.

Key Questions Answered

– How will biosimilar penetration impact the HER2-positive breast cancer market, especially following the launch of trastuzumab biosimilars in the 8MM?
– How will new pipeline agents such as Ibrance and neratinib impact the HER2-positive breast cancer market?
– The HER2-positive breast cancer market is characterized by a number of unmet needs in the current treatments. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?
– What impact will the approval of Roche’s Perjeta in the adjuvant setting following data from the Aphinity trial have on the HER2-positive breast cancer market? What will be the drug’s peak sales, and why?

Scope

– Overview of HER2-positive breast cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
– Annualized HER2-positive breast cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in nine patient segments and two treatment strategies (episodic and prophylactic treatment), forecast from 2016 to 2026.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HER2-positive breast cancer therapeutics market.
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HER2-positive breast cancer. The most promising candidate in Phase III development is profiled.
– Analysis of the current and future market competition in the global HER2-positive breast cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global HER2-positive breast cancer market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2-positive breast cancer market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Parkinson’s Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects

Parkinson's Disease and Behavioral Complications: PD Therapies Dominate First-in-Class Pipeline, with Novel Target Classes Demonstrating Potential Disease-Modifying Effects Summary Parkinson's disease (PD), a progressive neurological disorder that affects movement control, is associated with considerable quality of life impairments and burden of care, particularly in the advanced disease stages. Cognitive and behavioral complications of PD are common. PD-associated dementia and PD-associated psychosis are both highly prevalent and associated with a large disease burden. There is a pressing unmet need within PD, PD-associated dementia, and PD-associated psychosis for more effective disease-modifying pharmacotherapies. Although current therapies can provide patients with symptomatic relie......
$6995

Obesity: Gut Hormone Receptors Retain Commercial Prominence

Obesity: Gut Hormone Receptors Retain Commercial Prominence Summary Obesity is a chronic and potentially fatal disease. The most prevalent metabolic disorder affecting people today, obesity requires multidisciplinary continuing treatment. Despite the market's clinical and regulatory challenges, the obesity pipeline is robust and contains a high level of diversity in both molecule types and molecular targets, which is in line with its multifactorial etiology. The primary concern within the market is the need for medications that adequately address the unmet clinical needs in the overweight and obese population, namely efficacious and safe therapies. This report assesses first-in-class innovation across the obesity pipeline. Scope - The obesity pipeline is robust and contains a high leve......
$6995

Hepatitis B: Competitive Landscape to 2027

Hepatitis B: Competitive Landscape to 2027 Summary Hepatitis B is a viral infection of the liver that can become chronic in young children, especially newborns to mothers with HBV infections, and people with compromised immune systems. Chronic hepatitis B is defined as measurable Hepatitis surface antigen (HBsAg) levels for more than six months after an acute infection. Despite the existence of prophylactic vaccines, hepatitis B remains a global public health threat, with approximately 257 million people worldwide living with chronic HBV infections. Chronic hepatitis B cannot be cured and patients have elevated risks of developing liver cirrhosis and hepatocellular carcinoma (HCC). This report provides an assessment of the pipeline, clinical, and commercial landscape of Hepatitis B. Ov......
$3495

Pediatric Vaccines: Epidemiology Forecast to 2028

Pediatric Vaccines: Epidemiology Forecast to 2028 Summary The administration of a vaccine, referred to as vaccination, elicits an immune response that prevents an individual from developing a specific disease when exposed to the corresponding infectious agent in the future. A successful vaccination results in immunization, where the individual is deemed immune to the disease. Routine immunization programs aim to protect children at an early age, when they are the most vulnerable to disease. Prior to the discovery of vaccines, several infectious diseases claimed the lives of millions of children each year. GlobalData epidemiologists utilized comprehensive, country-specific vaccination rate data from nationally representative public health surveillance systems and databases to arrive at ......
$3995

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) Global Clinical Trials Review, H1, 2019" provides an overview of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based ......
$2500

Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019

Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Chronic Urticaria Or Hives Global Clinical Trials Review, H1, 2019" provides an overview of Chronic Urticaria Or Hives clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Urticaria Or Hives. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary databas......
$2500

Cryptosporidiosis Global Clinical Trials Review, H1, 2019

Cryptosporidiosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Cryptosporidiosis Global Clinical Trials Review, H1, 2019" provides an overview of Cryptosporidiosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cryptosporidiosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500

Colitis Global Clinical Trials Review, H1, 2019

Colitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Colitis Global Clinical Trials Review, H1, 2019" provides an overview of Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on Colitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated fro......
$2500

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019

Degenerative Scoliosis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Degenerative Scoliosis Global Clinical Trials Review, H1, 2019" provides an overview of Degenerative Scoliosis clinical trials scenario. This report provides top line data relating to the clinical trials on Degenerative Scoliosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrac......
$2500

Conjunctivitis Global Clinical Trials Review, H1, 2019

Conjunctivitis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Conjunctivitis Global Clinical Trials Review, H1, 2019" provides an overview of Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy